PRECAUTIONS O
General O
The O
lowest O
possible O
dose O
of O
corticosteroids O
should O
be O
used O
to O
control O
the O
condition O
under O
treatment O
. O

When O
reduction O
in O
dosage O
is O
possible O
, O
the O
reduction O
should O
be O
gradual O
. O

Since O
complications O
of O
treatment O
with O
corticosteroids O
are O
dependent O
on O
the O
size O
of O
the O
dose O
and O
the O
duration O
of O
treatment O
, O
a O
risk/benefit O
decision O
must O
be O
made O
in O
each O
individual O
case O
as O
to O
dose O
and O
duration O
of O
treatment O
and O
as O
to O
whether O
daily O
or O
intermittent O
therapy O
should O
be O
used O
. O

Kaposi B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
sarcoma I-OSE_Labeled_AE
has O
been O
reported O
to O
occur O
in O
patients O
receiving O
corticosteroid O
therapy O
, O
most O
often O
for O
chronic O
conditions O
. O

Discontinuation O
of O
corticosteroids O
may O
result O
in O
clinical O
improvement O
. O

Cardio-Renal O
As O
sodium B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
with O
resultant O
edema B-NonOSE_AE
and O
potassium B-NonOSE_AE
loss I-NonOSE_AE
may O
occur O
in O
patients O
receiving O
corticosteroids O
, O
these O
agents O
should O
be O
used O
with O
caution O
in O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
hypertension B-Not_AE_Candidate
, O
or O
renal B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
Endocrine O
Drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
secondary I-OSE_Labeled_AE
adrenocortical I-OSE_Labeled_AE
insufficiency I-OSE_Labeled_AE
may O
be O
minimized O
by O
gradual O
reduction O
of O
dosage O
. O

This O
type O
of O
relative O
insufficiency O
may O
persist O
for O
months O
after O
discontinuation O
of O
therapy O
; O
therefore O
, O
in O
any O
situation O
of O
stress B-Not_AE_Candidate
occurring O
during O
that O
period O
, O
hormone O
therapy O
should O
be O
reinstituted O
. O

Since O
mineralocorticoid B-NonOSE_AE
secretion I-NonOSE_AE
may O
be O
impaired I-NonOSE_AE
, O
salt O
and/or O
a O
mineralocorticoid O
should O
be O
administered O
concurrently O
. O

Gastrointestinal O
Steroids O
should O
be O
used O
with O
caution O
in O
active O
or O
latent O
peptic B-Not_AE_Candidate
ulcers I-Not_AE_Candidate
, O
diverticulitis B-Not_AE_Candidate
, O
fresh B-Not_AE_Candidate
intestinal I-Not_AE_Candidate
anastomoses I-Not_AE_Candidate
, O
and O
nonspecific O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
since O
they O
may O
increase O
the O
risk O
of O
a O
perforation B-NonOSE_AE
. O

Signs O
of O
peritoneal B-NonOSE_AE
irritation I-NonOSE_AE
following O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
in O
patients O
receiving O
corticosteroids O
may O
be O
minimal O
or O
absent O
. O

There O
is O
an O
enhanced O
effect O
due O
to O
decreased O
metabolism O
of O
corticosteroids O
in O
patients O
with O
cirrhosis B-Not_AE_Candidate
. O

Musculoskeletal O
Corticosteroids O
decrease B-OSE_Labeled_AE
bone I-OSE_Labeled_AE
formation I-OSE_Labeled_AE
and O
increase B-OSE_Labeled_AE
bone I-OSE_Labeled_AE
resorption I-OSE_Labeled_AE
both O
through O
their O
effect B-OSE_Labeled_AE
on I-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
regulation I-OSE_Labeled_AE
( O
i.e. O
, O
decreasing O
absorption O
and O
increasing O
excretion O
) O
and O
inhibition B-OSE_Labeled_AE
of I-OSE_Labeled_AE
osteoblast I-OSE_Labeled_AE
function I-OSE_Labeled_AE
. O

This O
, O
together O
with O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
protein I-NonOSE_AE
matrix I-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
bone I-NonOSE_AE
secondary O
to O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
catabolism I-OSE_Labeled_AE
, O
and O
reduced B-OSE_Labeled_AE
sex I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
production I-OSE_Labeled_AE
, O
may O
lead O
to O
inhibition B-OSE_Labeled_AE
of I-OSE_Labeled_AE
bone I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in O
pediatric O
patients O
and O
the O
development O
of O
osteoporosis B-OSE_Labeled_AE
at O
any O
age O
. O

Special O
consideration O
should O
be O
given O
to O
patients O
at O
increased O
risk O
of O
osteoporosis B-Not_AE_Candidate
( O
e.g. O
, O
postmenopausal B-Not_AE_Candidate
women O
) O
before O
initiating O
corticosteroid O
therapy O
. O

Neuro-Psychiatric O
Although O
controlled O
clinical O
trials O
have O
shown O
corticosteroids O
to O
be O
effective O
in O
speeding O
the O
resolution O
of O
acute B-Not_AE_Candidate
exacerbations I-Not_AE_Candidate
of I-Not_AE_Candidate
multiple I-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
, O
they O
do O
not O
show O
that O
they O
affect O
the O
ultimate O
outcome O
or O
natural O
history O
of O
the O
disease O
. O

The O
studies O
do O
show O
that O
relatively O
high O
doses O
of O
corticosteroids O
are O
necessary O
to O
demonstrate O
a O
significant O
effect O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

An O
acute B-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
has O
been O
observed O
with O
the O
use O
of O
high O
doses O
of O
corticosteroids O
, O
most O
often O
occurring O
in O
patients O
with O
disorders B-Not_AE_Candidate
of I-Not_AE_Candidate
neuromuscular I-Not_AE_Candidate
transmission I-Not_AE_Candidate
( O
e.g. O
, O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
) O
, O
or O
in O
patients O
receiving O
concomitant O
therapy O
with O
neuromuscular O
blocking O
drugs O
( O
e.g. O
, O
pancuronium O
) O
. O

This O
acute B-NonOSE_AE
myopathy I-NonOSE_AE
is O
generalized O
, O
may O
involve O
ocular O
and O
respiratory O
muscles O
, O
and O
may O
result O
in O
quadriparesis B-NonOSE_AE
. O

Elevation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
kinase I-OSE_Labeled_AE
may O
occur O
. O

Clinical O
improvement O
or O
recovery O
after O
stopping O
corticosteroids O
may O
require O
weeks O
to O
years O
. O

Psychic B-OSE_Labeled_AE
derangements I-OSE_Labeled_AE
may O
appear O
when O
corticosteroids O
are O
used O
, O
ranging O
from O
euphoria B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
mood B-OSE_Labeled_AE
swings I-OSE_Labeled_AE
, O
personality B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
and O
severe B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
to O
frank O
psychotic B-OSE_Labeled_AE
manifestations I-OSE_Labeled_AE
. O

Also O
, O
existing O
emotional B-OSE_Labeled_AE
instability I-OSE_Labeled_AE
or O
psychotic O
tendencies O
may O
be O
aggravated I-OSE_Labeled_AE
by O
corticosteroids O
. O

Ophthalmic O
lntraocular B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
may O
become O
elevated I-OSE_Labeled_AE
in O
some O
individuals O
. O

If O
steroid O
therapy O
is O
continued O
for O
more O
than O
6 O
weeks O
, O
intraocular O
pressure O
should O
be O
monitored O
. O

Information O
for O
Patients O
Patients O
should O
be O
warned O
not O
to O
discontinue O
the O
use O
of O
corticosteroids O
abruptly O
or O
without O
medical O
supervision O
. O

As O
prolonged O
use O
may O
cause O
adrenal B-NonOSE_AE
insufficiency I-NonOSE_AE
and O
make O
patients O
dependent B-NonOSE_AE
on O
corticosteroids O
, O
they O
should O
advise O
any O
medical O
attendants O
that O
they O
are O
taking O
corticosteroids O
and O
they O
should O
seek O
medical O
advice O
at O
once O
should O
they O
develop O
an O
acute B-NonOSE_AE
illness I-NonOSE_AE
including O
fever B-NonOSE_AE
or O
other O
signs O
of O
infection B-NonOSE_AE
. O

Following O
prolonged O
therapy O
, O
withdrawal O
of O
corticosteroids O
may O
result O
in O
symptoms O
of O
the O
corticosteroid B-NonOSE_AE
withdrawal I-NonOSE_AE
syndrome I-NonOSE_AE
including O
, O
myalgia B-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
and O
malaise B-NonOSE_AE
. O

Persons O
who O
are O
on O
corticosteroids O
should O
be O
warned O
to O
avoid O
exposure O
to O
chickenpox B-NonOSE_AE
or O
measles B-NonOSE_AE
. O

Patients O
should O
also O
be O
advised O
that O
if O
they O
are O
exposed O
, O
medical O
advice O
should O
be O
sought O
without O
delay O
. O

Drug O
Interactions O
Aminoglutethimide O
: O
Aminoglutethimide O
may O
diminish B-NonOSE_AE
adrenal I-NonOSE_AE
suppression I-NonOSE_AE
by O
corticosteroids O
. O

Amphotericin O
B O
Injection O
and O
Potassium-depleting O
agents O
: O
When O
corticosteroids O
are O
administered O
concomitantly O
with O
potassium-depleting O
agents O
( O
e.g. O
, O
amphotericin O
B O
, O
diuretics O
) O
, O
patients O
should O
be O
observed O
closely O
for O
development O
of O
hypokalemia B-NonOSE_AE
. O

In O
addition O
, O
there O
have O
been O
cases O
reported O
in O
which O
concomitant O
use O
of O
amphotericin O
B O
and O
hydrocortisone O
was O
followed O
by O
cardiac B-NonOSE_AE
enlargement I-NonOSE_AE
and O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

Antibiotics O
: O
Macrolide O
antibiotics O
have O
been O
reported O
to O
cause O
a O
significant O
decrease O
in O
corticosteroid O
clearance O
( O
see O
Drug O
Interactions O
: O
Hepatic O
Enzyme O
Inducers O
, O
Inhibitors O
and O
Substrates O
) O
. O

Anticholinesterases O
: O
Concomitant O
use O
of O
anticholinesterase O
agents O
and O
corticosteroids O
may O
produce O
severe B-NonOSE_AE
weakness I-NonOSE_AE
in O
patients O
with O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
. O

If O
possible O
, O
anticholinesterase O
agents O
should O
be O
withdrawn O
at O
least O
24 O
hours O
before O
initiating O
corticosteroid O
therapy O
. O

Anticoagulants O
, O
Oral O
: O
Co-administration O
of O
corticosteroids O
and O
warfarin O
usually O
results O
in O
inhibition O
of O
response O
to O
warfarin O
, O
although O
there O
have O
been O
some O
conflicting O
reports O
. O

Therefore O
, O
coagulation O
indices O
should O
be O
monitored O
frequently O
to O
maintain O
the O
desired O
anticoagulant B-NonOSE_AE
effect I-NonOSE_AE
. O

Antidiabetics O
: O
Because O
corticosteroids O
may O
increase B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
, O
dosage O
adjustments O
of O
antidiabetic O
agents O
may O
be O
required O
. O

Antitubercular O
Drugs O
: O
Serum O
concentrations O
of O
isoniazid O
may O
be O
decreased O
. O

Cholestyramine O
: O
Cholestyramine O
may O
increase O
the O
clearance O
of O
corticosteroids O
. O

Cyclosporine O
: O
Increased O
activity O
of O
both O
cyclosporine O
and O
corticosteroids O
may O
occur O
when O
the O
two O
are O
used O
concurrently O
. O

Convulsions B-NonOSE_AE
have O
been O
reported O
with O
this O
concurrent O
use O
. O

Dexamethasone O
Suppression O
Test O
( O
DST O
) O
: O
False B-NonOSE_AE
- I-NonOSE_AE
negative I-NonOSE_AE
results I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
dexamethasone I-NonOSE_AE
suppression I-NonOSE_AE
test I-NonOSE_AE
( I-NonOSE_AE
DST I-NonOSE_AE
) O
in O
patients O
being O
treated O
with O
indomethacin O
have O
been O
reported O
. O

Thus O
, O
results O
of O
the O
DST O
should O
be O
interpreted O
with O
caution O
in O
these O
patients O
. O

Digitalis O
Glycosides O
: O
Patients O
on O
digitalis O
glycosides O
may O
be O
at O
increased O
risk O
of O
arrhythmias B-NonOSE_AE
due O
to O
hypokalemia B-NonOSE_AE
. O

Ephedrine O
: O
Ephedrine O
may O
enhance O
the O
metabolic O
clearance O
of O
corticosteroids O
, O
resulting O
in O
decreased O
blood O
levels O
and O
lessened O
physiologic O
activity O
, O
thus O
requiring O
an O
increase O
in O
corticosteroid O
dosage O
. O

Estrogens O
, O
Including O
Oral O
Contraceptives O
: O
Estrogens O
may O
decrease O
the O
hepatic O
metabolism O
of O
certain O
corticosteroids O
, O
thereby O
increasing O
their O
effect O
. O

Hepatic O
Enzyme O
Inducers O
, O
Inhibitors O
and O
Substrates O
: O
Drugs O
which O
induce O
cytochrome O
P450 O
3A4 O
( O
CYP O
3A4 O
) O
enzyme O
activity O
( O
e.g. O
, O
barbiturates O
, O
phenytoin O
, O
carbamazepine O
, O
rifampin O
) O
may O
enhance O
the O
metabolism O
of O
corticosteroids O
and O
require O
that O
the O
dosage O
of O
the O
corticosteroid O
be O
increased O
. O

Drugs O
which O
inhibit O
CYP O
3A4 O
( O
e.g. O
, O
ketoconazole O
, O
macrolide O
antibiotics O
such O
as O
erythromycin O
) O
have O
the O
potential O
to O
result O
in O
increased O
plasma O
concentrations O
of O
corticosteroids O
. O

Dexamethasone O
is O
a O
moderate O
inducer O
of O
CYP O
3A4 O
. O

Co-adminstration O
with O
other O
drugs O
that O
are O
metabolized O
by O
CYP O
3A4 O
( O
e.g. O
, O
indinavir O
, O
erythromycin O
) O
may O
increase O
their O
clearance O
, O
resulting O
in O
decreased O
plasma O
concentration O
. O

Ketoconazole O
: O
Ketoconazole O
has O
been O
reported O
to O
decrease O
the O
metabolism O
of O
certain O
corticosteroids O
by O
up O
to O
60 O
% O
, O
leading O
to O
increased O
risk O
of O
corticosteroid O
side O
effects O
. O

In O
addition O
, O
ketoconazole O
alone O
can O
inhibit B-NonOSE_AE
adrenal I-NonOSE_AE
corticosteroid I-NonOSE_AE
synthesis I-NonOSE_AE
and O
may O
cause O
adrenal B-NonOSE_AE
insufficiency I-NonOSE_AE
during O
corticosteroid O
withdrawal O
. O

Nonsteroidal O
Anti-Inflammatory O
Agents O
( O
NSAIDS O
) O
: O
Concomitant O
use O
of O
aspirin O
( O
or O
other O
nonsteroidal O
antiinflammatory O
agents O
) O
and O
corticosteroids O
increases O
the O
risk O
of O
gastrointestinal B-NonOSE_AE
side I-NonOSE_AE
effects I-NonOSE_AE
. O

Aspirin O
should O
be O
used O
cautiously O
in O
conjunction O
with O
corticosteroids O
in O
hypoprothrombinemia B-Not_AE_Candidate
. O

The O
clearance O
of O
salicylates O
may O
be O
increased O
with O
concurrent O
use O
of O
corticosteroids O
. O

Phenytoin O
: O
In O
post-marketing O
experience O
, O
there O
have O
been O
reports O
of O
both O
increases O
and O
decreases O
in O
phenytoin O
levels O
with O
dexamethasone O
co-administration O
, O
leading O
to O
alterations O
in O
seizure B-NonOSE_AE
control O
. O

Skin O
Tests O
: O
Corticosteroids O
may O
suppress B-NonOSE_AE
reactions I-NonOSE_AE
to I-NonOSE_AE
skin I-NonOSE_AE
tests I-NonOSE_AE
. O

Thalidomide O
: O
Co-administration O
with O
thalidomide O
should O
be O
employed O
cautiously O
, O
as O
toxic B-NonOSE_AE
epidermal I-NonOSE_AE
necrolysis I-NonOSE_AE
has O
been O
reported O
with O
concomitant O
use O
. O

Vaccines O
: O
Patients O
on O
corticosteroid O
therapy O
may O
exhibit O
a O
diminished O
response O
to O
toxoids O
and O
live O
or O
inactivated O
vaccines O
due O
to O
inhibition B-NonOSE_AE
of I-NonOSE_AE
antibody I-NonOSE_AE
response I-NonOSE_AE
. O

Corticosteroids O
may O
also O
potentiate B-NonOSE_AE
the I-NonOSE_AE
replication I-NonOSE_AE
of I-NonOSE_AE
some I-NonOSE_AE
organisms I-NonOSE_AE
contained I-NonOSE_AE
in I-NonOSE_AE
live I-NonOSE_AE
attenuated I-NonOSE_AE
vaccines I-NonOSE_AE
. O

Routine O
administration O
of O
vaccines O
or O
toxoids O
should O
be O
deferred O
until O
corticosteroid O
therapy O
is O
discontinued O
if O
possible O
( O
see O
WARNINGS O
: O
Infections O
: O
Vaccination O
) O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
No O
adequate O
studies O
have O
been O
conducted O
in O
animals O
to O
determine O
whether O
corticosteroids O
have O
a O
potential O
for O
carcinogenesis B-NonOSE_AE
or O
mutagenesis B-NonOSE_AE
. O

Steroids O
may O
increase B-OSE_Labeled_AE
or O
decrease O
motility I-OSE_Labeled_AE
and O
number O
of I-OSE_Labeled_AE
spermatozoa I-OSE_Labeled_AE
in O
some O
patients O
. O

Pregnancy O
Teratogenic O
Effects O
: O
Pregnancy B-NonOSE_AE
Category O
C O
: O
Corticosteroids O
have O
been O
shown O
to O
be O
teratogenic B-NonOSE_AE
in O
many O
species O
when O
given O
in O
doses O
equivalent O
to O
the O
human O
dose O
. O

Animal O
studies O
in O
which O
corticosteroids O
have O
been O
given O
to O
pregnant B-NonOSE_AE
mice O
, O
rats O
, O
and O
rabbits O
have O
yielded O
an O
increased O
incidence O
of O
cleft B-NonOSE_AE
palate I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
offspring I-NonOSE_AE
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

Corticosteroids O
should O
be O
used O
during O
pregnancy B-Not_AE_Candidate
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Infants B-NonOSE_AE
born O
to O
mothers O
who O
have O
received O
substantial O
doses O
of O
corticosteroids O
during O
pregnancy O
shou O
ld B-Not_AE_Candidate
be I-Not_AE_Candidate
car I-Not_AE_Candidate
efully O
observed O
for O
signs O
of O
hypoadrenalism I-NonOSE_AE
. O

Nursing O
Mothers O
Systemically O
administered O
corticosteroids O
appear O
in O
human O
milk O
and O
could O
suppress B-OSE_Labeled_AE
growth I-OSE_Labeled_AE
, O
interfere B-OSE_Labeled_AE
with I-OSE_Labeled_AE
endogenous I-OSE_Labeled_AE
corticosteroid I-OSE_Labeled_AE
production I-OSE_Labeled_AE
, O
or O
cause O
other O
untoward O
effects O
. O

Because O
of O
the O
potential O
for O
serious O
adverse B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in I-OSE_Labeled_AE
nursing I-OSE_Labeled_AE
infants I-OSE_Labeled_AE
from I-OSE_Labeled_AE
corticosteroids I-OSE_Labeled_AE
, O
a O
decision O
should O
be O
made O
whether O
to O
discontinue O
nursing O
or O
to O
discontinue O
the O
drug O
, O
taking O
into O
account O
the O
importance O
of O
the O
drug O
to O
the O
mother O
. O

Pediatric O
Use O
The O
efficacy O
and O
safety O
of O
corticosteroids O
in O
the O
pediatric O
population O
are O
based O
on O
the O
well-established O
course O
of O
effect O
of O
corticosteroids O
, O
which O
is O
similar O
in O
pediatric O
and O
adult O
populations O
. O

Published O
studies O
provide O
evidence O
of O
efficacy O
and O
safety O
in O
pediatric O
patients O
for O
the O
treatment O
of O
nephrotic B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
( O
patients O
> O
2 O
years O
of O
age O
) O
, O
and O
aggressive O
lymphomas B-Not_AE_Candidate
and O
leukemias B-Not_AE_Candidate
( O
patients O
> O
1 O
month O
of O
age O
) O
. O

Other O
indications O
for O
pediatric O
use O
of O
corticosteroids O
, O
e.g. O
, O
severe O
asthma B-Not_AE_Candidate
and O
wheezing B-Not_AE_Candidate
, O
are O
based O
on O
adequate O
and O
well-controlled O
trials O
conducted O
in O
adults O
, O
on O
the O
premises O
that O
the O
course O
of O
the O
diseases O
and O
their O
pathophysiology O
are O
considered O
to O
be O
substantially O
similar O
in O
both O
populations O
. O

The O
adverse O
effects O
of O
corticosteroids O
in O
pediatric O
patients O
are O
similar O
to O
those O
in O
adults O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

Like O
adults O
, O
pediatric O
patients O
should O
be O
carefully O
observed O
with O
frequent O
measurements O
of O
blood O
pressure O
, O
weight O
, O
height O
, O
intraocular O
pressure O
, O
and O
clinical O
evaluation O
for O
the O
presence O
of O
infection B-NonOSE_AE
, O
psychosocial B-NonOSE_AE
disturbances I-NonOSE_AE
, O
thromboembolism B-NonOSE_AE
, O
peptic B-NonOSE_AE
ulcers I-NonOSE_AE
, O
cataracts B-NonOSE_AE
, O
and O
osteoporosis B-NonOSE_AE
. O

Pediatric O
patients O
who O
are O
treated O
with O
corticosteroids O
by O
any O
route O
, O
including O
systemically O
administered O
corticosteroids O
, O
may O
experience O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
their I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
velocity I-OSE_Labeled_AE
. O

This O
negative B-OSE_Labeled_AE
impact I-OSE_Labeled_AE
of O
corticosteroids O
on I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
has O
been O
observed O
at O
low O
systemic O
doses O
and O
in O
the O
absence O
of O
laboratory O
evidence O
of O
hypothalamic B-NonOSE_AE
- I-NonOSE_AE
pituitary I-NonOSE_AE
- I-NonOSE_AE
adrenal I-NonOSE_AE
( I-NonOSE_AE
HPA I-NonOSE_AE
) I-NonOSE_AE
axis I-NonOSE_AE
suppression I-NonOSE_AE
( O
i.e. O
, O
cosyntropin O
stimulation O
and O
basal O
cortisol O
plasma O
levels O
) O
. O

Growth O
velocity O
may O
therefore O
be O
a O
more O
sensitive O
indicator O
of O
systemic O
corticosteroid O
exposure O
in O
pediatric O
patients O
than O
some O
commonly O
used O
tests O
of O
HPA O
axis O
function O
. O

The O
linear O
growth O
of O
pediatric O
patients O
treated O
with O
corticosteroids O
should O
be O
monitored O
, O
and O
the O
potential O
growth B-NonOSE_AE
effects I-NonOSE_AE
of O
prolonged O
treatment O
should O
be O
weighed O
against O
clinical O
benefits O
obtained O
and O
the O
availability O
of O
treatment O
alternatives O
. O

In O
order O
to O
minimize O
the O
potential O
growth B-NonOSE_AE
effects I-NonOSE_AE
of O
corticosteroids O
, O
pediatric O
patients O
should O
be O
titrated O
to O
the O
lowest O
effective O
dose O
. O

Geriatric O
Use O
Clinical O
studies O
did O
not O
include O
sufficient O
numbers O
of O
subjects O
aged O
65 O
and O
over O
to O
determine O
whether O
they O
respond O
differently O
from O
younger O
subjects O
. O

Other O
reported O
clinical O
experience O
has O
not O
identified O
differences O
in O
responses O
between O
the O
elderly O
and O
younger O
patients O
. O

In O
general O
, O
dose O
selection O
for O
an O
elderly O
patient O
should O
be O
cautious O
, O
usually O
starting O
at O
the O
low O
end O
of O
the O
dosing O
range O
, O
reflecting O
the O
greater O
frequency O
of O
decreased B-Not_AE_Candidate
hepatic I-Not_AE_Candidate
, O
renal O
, O
or O
cardiac O
function I-Not_AE_Candidate
, O
and O
of O
concomitant O
disease O
or O
other O
drug O
therapy O
. O

In O
particular O
, O
the O
increased O
risk O
of O
diabetes B-NonOSE_AE
mellitus I-NonOSE_AE
, O
fluid B-NonOSE_AE
retention I-NonOSE_AE
and O
hypertension B-NonOSE_AE
in O
elderly O
patients O
treated O
with O
corticosteroids O
should O
be O
considered O
. O

